Tamburrino L, Salvianti F, Marchiani S et al (2012) Androgen receptor (AR) expression in prostate cancer and progression of the tumor: Lessons from cell lines, animal models and human specimens. Steroids 77:996–1001. https://doi.org/10.1016/J.STEROIDS.2012.01.008

Article  CAS  PubMed  Google Scholar 

Liu JM, Liu YP, Chuang HC et al (2020) Androgen deprivation therapy for prostate cancer and the risk of hematologic disorders. PLoS One 15. https://doi.org/10.1371/JOURNAL.PONE.0229263

Gunner C, Gulamhusein A, Rosario DJ (2016) The modern role of androgen deprivation therapy in the management of localised and locally advanced prostate cancer. J Clin Urol 9:24. https://doi.org/10.1177/2051415816654048

Article  PubMed  PubMed Central  Google Scholar 

Helsen C, Van Den Broeck T, Voet A et al (2014) Androgen receptor antagonists for prostate cancer therapy. Endocr Relat Cancer 21:T105–T118. https://doi.org/10.1530/ERC-13-0545

Article  CAS  PubMed  Google Scholar 

Erdogan B, Kostek O, Bekirhacioglu M (2018) Enzalutamide in Prostate Cancer, A Review on Enzalutamide and cancer. Eurasian J Med Oncol 2:121–129. https://doi.org/10.14744/EJMO.2018.72098

Westaby D, Maza MDLDFD La, Paschalis A et al (2022) A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer. Annu Rev Pharmacol Toxicol 62:052220–015912. https://doi.org/10.1146/ANNUREV-PHARMTOX-052220-015912

Higano CS (2020) Cardiovascular Disease and Androgen Axis-Targeted Drugs for Prostate Cancer. N Engl J Med 382:2257–2259. https://doi.org/10.1056/NEJME2016433/SUPPL_FILE/NEJME2016433_DISCLOSURES.PDF

Article  CAS  PubMed  Google Scholar 

Mishra A, Hourigan D, Lindsay AJ (2022) Inhibition of the endosomal recycling pathway downregulates HER2 activation and overcomes resistance to tyrosine kinase inhibitors in HER2-positive breast cancer. Cancer Lett 529:153–167. https://doi.org/10.1016/j.canlet.2022.01.003

Article  CAS  PubMed  Google Scholar 

O’Sullivan MJ, Lindsay AJ (2020) The Endosomal Recycling Pathway-At the Crossroads of the Cell. Int J Mol Sci 2020:6074. https://doi.org/10.3390/ijms21176074

Article  CAS  Google Scholar 

Fletcher K, Alkurashi MH, Lindsay AJ (2023) Endosomal recycling inhibitors downregulate estrogen receptor-alpha and synergise with endocrine therapies. Breast Cancer Res Treat Under Revision

Anestis A, Zoi I, Papavassiliou AG, Karamouzis MV (2020) Androgen Receptor in Breast Cancer—Clinical and Preclinical Research Insights. Molecules 25. https://doi.org/10.3390/MOLECULES25020358

Lafront C, Germain L, Weidmann C, Audet-Walsh É (2020) A Systematic Study of the Impact of Estrogens and Selective Estrogen Receptor Modulators on Prostate Cancer Cell Proliferation. Sci Rep 10(1):1–12. https://doi.org/10.1038/s41598-020-60844-3

Kaiser J, Stockert RJ, Wolkoff AW (1988) Effect of monensin on receptor recycling during continuous endocytosis of asialoorosomucoid. Exp Cell Res 174:472–480. https://doi.org/10.1016/0014-4827(88)90316-3

Article  CAS  PubMed  Google Scholar 

Lindsay AJ, McCaffrey MW, Lindsay AJ, McCaffrey MW (2016) Rab coupling protein mediated endosomal recycling of N-cadherin influences cell motility. Oncotarget 8:104717–104732. https://doi.org/10.18632/ONCOTARGET.10513

Lin HK, Altuwaijri S, Lin WJ et al (2002) Proteasome Activity Is Required for Androgen Receptor Transcriptional Activity via Regulation of Androgen Receptor Nuclear Translocation and Interaction with Coregulators in Prostate Cancer Cells. J Biol Chem 277:36570–36576. https://doi.org/10.1074/JBC.M204751200

Article  CAS  PubMed  Google Scholar 

Guo H, Wu Y, Nouri M et al (2021) Androgen receptor and MYC equilibration centralizes on developmental super-enhancer. Nat Commun 12. https://doi.org/10.1038/S41467-021-27077-Y

Li MT, Richter F, Chang C et al (2002) Androgen and retinoic acid interaction in LNCaP cells, effects on cell proliferation and expression of retinoic acid receptors and epidermal growth factor receptor. BMC Cancer 2:1–8. https://doi.org/10.1186/1471-2407-2-16/FIGURES/5

Article  CAS  Google Scholar 

Ni M, Chen Y, Lim E et al (2011) Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer. Cancer Cell 20:119. https://doi.org/10.1016/J.CCR.2011.05.026

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mehta A, Tripathy D (2014) Co-targeting estrogen receptor and HER2 pathways in breast cancer. Breast 23:2–9. https://doi.org/10.1016/J.BREAST.2013.09.006

Article  PubMed  Google Scholar 

Freeman MR (2004) HER2/HER3 heterodimers in prostate cancer: Whither HER1/EGFR? Cancer Cell 6:427–428. https://doi.org/10.1016/J.CCR.2004.10.018

Article  CAS  PubMed  Google Scholar 

Craft N, Shostak Y, Carey M, Sawyers CL (1999) A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5(3):280–285. https://doi.org/10.1038/6495

Hoadley KA, Yau C, Hinoue T et al (2018) Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell 173:291. https://doi.org/10.1016/J.CELL.2018.03.022

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev

Kimlin LC, Casagrande G, Virador VM (2013) In vitro three-dimensional (3D) models in cancer research: An update. Mol Carcinog 52:167–182. https://doi.org/10.1002/MC.21844

Article  PubMed  Google Scholar 

Vander AA, Cao J, Li X (2018) Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer. Front Oncol 8:180. https://doi.org/10.3389/FONC.2018.00180

Article  Google Scholar 

Parachoniak CA, Luo Y, Abella JV et al (2011) GGA3 functions as a switch to promote met receptor recycling, essential for sustained ERK and cell migration. Dev Cell 20:751–763. https://doi.org/10.1016/j.devcel.2011.05.007

Article  CAS  PubMed  PubMed Central  Google Scholar 

Amornphimoltham P, Rechache K, Thompson J et al (2007) Rab-coupling protein coordinates recycling of alpha5beta1 integrin and EGFR1 to promote cell migration in 3D microenvironments. Mol Biol Cell 9:2799–2812. https://doi.org/10.1091/mbc.9.11.3241

Article  Google Scholar 

Pietilä M, Sahgal P, Peuhu E et al (2019) SORLA regulates endosomal trafficking and oncogenic fitness of HER2. Nat Commun 10:1–16. https://doi.org/10.1038/s41467-019-10275-0

Article  CAS  Google Scholar 

Al-Akhrass H, Conway JRW, Poulsen ASA et al (2021) A feed-forward loop between SorLA and HER3 determines heregulin response and neratinib resistance. Oncogene 40(7):1300–1317. https://doi.org/10.1038/s41388-020-01604-5

Van Weert AWM, Geuze HJ, Groothuis B, Stoorvogel W (2000) Primaquine interferes with membrane recycling from endosomes to the plasma membrane through a direct interaction with endosomes which does not involve neutralisation of endosomal pH nor osmotic swelling of endosomes. Eur J Cell Biol 79:394–399. https://doi.org/10.1078/0171-9335-00062

Article  PubMed  Google Scholar 

Gil V, Miranda S, Riisnaes R et al (2021) HER3 Is an Actionable Target in Advanced Prostate Cancer. Cancer Res 81:6207–6218. https://doi.org/10.1158/0008-5472.CAN-21-3360/670640/AM/HER3-IS-AN-ACTIONABLE-TARGET-IN-ADVANCED-PROSTATE

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fernando D, Rodrigo C, Rajapakse S (2011) Primaquine in vivax malaria: An update and review on management issues. Malar J 10:1–12. https://doi.org/10.1186/1475-2875-10-351/METRICS

Article  Google Scholar 

Blain M, Garrard A, Poppenga R et al (2017) Survival After Severe Rhabdomyolysis Following Monensin Ingestion. J Med Toxicol 13:259. https://doi.org/10.1007/S13181-017-0616-6

Article  PubMed  PubMed Central  Google Scholar 

Chung BM, Raja SM, Clubb RJ et al (2009) Aberrant trafficking of NSCLC-associated EGFR mutants through the endocytic recycling pathway promotes interaction with Src. BMC Cell Biol 10:84. https://doi.org/10.1186/1471-2121-10-84

Article  CAS  PubMed  PubMed Central  Google Scholar 

Park WH, Jung CW, Park JO et al (2003) Monensin inhibits the growth of renal cell carcinoma cells via cell cycle arrest or apoptosis. Int J Oncol 22:855–860. https://doi.org/10.3892/IJO.22.4.855/HTML

Article  CAS  PubMed  Google Scholar 

Deng Y, Zhang J, Wang Z et al (2015) Antibiotic monensin synergizes with EGFR inhibitors and oxaliplatin to suppress the proliferation of human ovarian cancer cells. Sci Rep 5. https://doi.org/10.1038/srep17523

Wang X, Wu X, Zhang Z et al (2018) Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway. Sci Rep 8. https://doi.org/10.1038/s41598-018-36214-5

Dayekh K, Johnson-Obaseki S, Corsten M et al (2014) Monensin inhibits epidermal growth factor receptor trafficking and activation: Synergistic cytotoxicity in combination with EGFR inhibitors. Mol Cancer Ther 13:2559–2571. https://doi.org/10.1158/1535-7163.MCT-13-1086/85531/AM/MONENSIN-INHIBITS-EPIDERMAL-GROWTH-FACTOR-RECEPTOR

Article  CAS  PubMed  Google Scholar 

Ketola K, Vainio P, Fey V et al (2010) Monensin Is a Potent Inducer of Oxidative Stress and Inhibitor of Androgen Signaling Leading to Apoptosis in Prostate Cancer Cells. Mol Cancer Ther 9:3175–3185. https://doi.org/10.1158/1535-7163.MCT-10-0368

Article  CAS  PubMed  Google Scholar 

Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–55. https://doi.org/10.1016/0065-2571(84)90007-4

Article  CAS  PubMed  Google Scholar 

Chou TC (2010) Drug combination studies and their synergy quantification using the chou-talalay method. Cancer Res 70:440–446

Article  CAS  PubMed  Google Scholar 

Chou TC, Martin N (2005) CompuSyn for drug combinations. A Computer Software for Quantitation of Synergism and Antagonism, and the Determination of IC50, ED50 and LD50 Values[PC software and user’s guide](ComboSyn, Paramus, NJ)

Brancato V, Oliveira JM, Correlo VM et al (2020) Could 3D models of cancer enhance drug screening? Biomaterials 232:119744. https://doi.org/10.1016/J.BIOMATERIALS.2019.119744

Article  CAS  PubMed  Google Scholar 

Cerami E, Gao J, Dogrusoz U et al (2012) The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data. Cancer Discov 2:401–404. https://doi.org/10.1158/2159-8290.CD-12-0095

Article  PubMed  Google Scholar